{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:44:26Z","timestamp":1795034666820,"version":"4.10.2"},"reference-count":239,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11010-025-05324-w","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:14:13Z","timestamp":1749449653000},"page":"5221-5242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The role of L-DOPA in neurological and neurodegenerative complications: a review"],"prefix":"10.1007","volume":"480","author":[{"given":"Sudheendra Rao","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bothe","family":"Thokchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Abbigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Mallikarjun","family":"Bhavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapam Riches","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Metri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh Babu","family":"Yarajarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"5324_CR1","doi-asserted-by":"publisher","first-page":"116448","DOI":"10.1016\/j.biopha.2024.116448","volume":"174","author":"M Liu","year":"2024","unstructured":"Liu M, Xue J, Cao Y et al (2024) The effects of nardosinone on levodopa intervention in the treatment of parkinson\u2019s disease. Biomed Pharmacother 174:116448. https:\/\/doi.org\/10.1016\/j.biopha.2024.116448","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5324_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00401-024-02739-5","volume":"147","author":"N Shebl","year":"2024","unstructured":"Shebl N, Salama M (2024) From metabolomics to proteomics: understanding the role of dopa decarboxylase in parkinson\u2019s disease. Scientific commentary on:\u201ccomprehensive proteomics of CSF, plasma and urine identify DDC and other biomarkers of early Parkinson\u2019s disease.\u201d Acta Neuropathol 147(1):88. https:\/\/doi.org\/10.1007\/s00401-024-02739-5","journal-title":"Acta Neuropathol"},{"key":"5324_CR3","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1007\/s12035-023-03684-2","volume":"61","author":"Z Sternberg","year":"2024","unstructured":"Sternberg Z (2024) Neurodegenerative etiology of aromatic l-amino acid decarboxylase deficiency: a novel concept for expanding treatment strategies. Mol Neurobiol 61:2996\u20133018. https:\/\/doi.org\/10.1007\/s12035-023-03684-2","journal-title":"Mol Neurobiol"},{"key":"5324_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","volume":"360","author":"EF Van Vliet","year":"2023","unstructured":"Van Vliet EF, Knol MJ, Schiffelers RM et al (2023) Levodopa-loaded nanoparticles for the treatment of Parkinson\u2019s disease. J Controlled Release 360:212\u2013224. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.026","journal-title":"J Controlled Release"},{"key":"5324_CR5","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.prenap.2024.100050","volume":"3","author":"J-J Ang","year":"2024","unstructured":"Ang J-J, Low B-S, Wong P-F (2024) Dopamine and central dopaminergic circuitry in neurodegenerative diseases: roles and mechanisms of action of natural phytochemicals. Pharmacol Res - Nat Prod 3:100050. https:\/\/doi.org\/10.1016\/j.prenap.2024.100050","journal-title":"Pharmacol Res - Nat Prod"},{"key":"5324_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.eehl.2024.08.002","volume":"3","author":"S Li","year":"2024","unstructured":"Li S, Qin S, Zeng H et al (2024) Adverse outcome pathway for the neurotoxicity of per- and polyfluoroalkyl substances: a systematic review. Eco-Environ Health 3:476\u2013493. https:\/\/doi.org\/10.1016\/j.eehl.2024.08.002","journal-title":"Eco-Environ Health"},{"key":"5324_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpsychires.2015.08.014","volume":"70","author":"BJ Jongkees","year":"2015","unstructured":"Jongkees BJ, Hommel B, K\u00fchn S, Colzato LS (2015) Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands\u2014A review. J Psychiatr Res 70:50\u201357. https:\/\/doi.org\/10.1016\/j.jpsychires.2015.08.014","journal-title":"J Psychiatr Res"},{"key":"5324_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cells10040735","volume":"10","author":"L Speranza","year":"2021","unstructured":"Speranza L, Di Porzio U, Viggiano D et al (2021) Dopamine: the neuromodulator of long-term synaptic plasticity. Rew Mov Control Cells 10:735. https:\/\/doi.org\/10.3390\/cells10040735","journal-title":"Rew Mov Control Cells"},{"key":"5324_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0300985820959231","volume":"58","author":"LG Lanigan","year":"2021","unstructured":"Lanigan LG, Russell DS, Woolard KD et al (2021) Comparative pathology of the peripheral nervous system. Vet Pathol 58:10\u201333. https:\/\/doi.org\/10.1177\/0300985820959231","journal-title":"Vet Pathol"},{"key":"5324_CR10","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.3390\/ijms23115954","volume":"23","author":"RI Teleanu","year":"2022","unstructured":"Teleanu RI, Niculescu A-G, Roza E et al (2022) Neurotransmitters\u2014key factors in neurological and neurodegenerative disorders of the central nervous system. Int J Mol Sci 23:5954. https:\/\/doi.org\/10.3390\/ijms23115954","journal-title":"Int J Mol Sci"},{"key":"5324_CR11","doi-asserted-by":"publisher","first-page":"101994","DOI":"10.1016\/j.arr.2023.101994","volume":"89","author":"M Nimgampalle","year":"2023","unstructured":"Nimgampalle M, Chakravarthy H, Sharma S et al (2023) Neurotransmitter systems in the etiology of major neurological disorders: emerging insights and therapeutic implications. Ageing Res Rev 89:101994. https:\/\/doi.org\/10.1016\/j.arr.2023.101994","journal-title":"Ageing Res Rev"},{"key":"5324_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.pjnns.2014.07.009","volume":"48","author":"W Brola","year":"2014","unstructured":"Brola W, Mitosek-Szewczyk K, Opara J (2014) Symptomatology and pathogenesis of different types of pain in multiple sclerosis. Neurol Neurochir Pol 48:272\u2013279. https:\/\/doi.org\/10.1016\/j.pjnns.2014.07.009","journal-title":"Neurol Neurochir Pol"},{"issue":"1","key":"5324_CR13","doi-asserted-by":"publisher","first-page":"01","DOI":"10.59680\/ishel.v2i1.982","volume":"2","author":"P Prameswari","year":"2024","unstructured":"Prameswari P (2024) Epilepsy as a disease affecting neural networks. Int Sci Health J 2(1):01\u201317. https:\/\/doi.org\/10.59680\/ishel.v2i1.982","journal-title":"Int Sci Health J"},{"key":"5324_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1177\/1535370221989263","volume":"246","author":"SM Sears","year":"2021","unstructured":"Sears SM, Hewett SJ (2021) Influence of glutamate and GABA transport on brain excitatory\/inhibitory balance. Exp Biol Med 246:1069\u20131083. https:\/\/doi.org\/10.1177\/1535370221989263","journal-title":"Exp Biol Med"},{"key":"5324_CR15","doi-asserted-by":"publisher","first-page":"664664","DOI":"10.3389\/fneur.2021.664664","volume":"12","author":"S Bhagavati","year":"2021","unstructured":"Bhagavati S (2021) Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy. Front Neurol 12:664664. https:\/\/doi.org\/10.3389\/fneur.2021.664664","journal-title":"Front Neurol"},{"key":"5324_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11033-024-09597-0","volume":"51","author":"R Dhapola","year":"2024","unstructured":"Dhapola R, Medhi B, HariKrishnaReddy D (2024) Insight into the pathophysiological advances and molecular mechanisms underlying cerebral stroke: current status. Mol Biol Rep 51:649. https:\/\/doi.org\/10.1007\/s11033-024-09597-0","journal-title":"Mol Biol Rep"},{"key":"5324_CR17","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.3390\/ijms23105796","volume":"23","author":"D Frank","year":"2022","unstructured":"Frank D, Zlotnik A, Boyko M, Gruenbaum BF (2022) The development of novel drug treatments for stroke patients: a review. Int J Mol Sci 23:5796. https:\/\/doi.org\/10.3390\/ijms23105796","journal-title":"Int J Mol Sci"},{"key":"5324_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M et al (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"key":"5324_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/978-3-031-68237-7_21","volume-title":"Neuroimmune pharmacology and therapeutics","author":"K Kwei","year":"2024","unstructured":"Kwei K, Przedborski S (2024) Neurodegeneration. In: Gendelman HE, Ikezu T (eds) Neuroimmune pharmacology and therapeutics. Springer Nature Switzerland, Cham, pp 345\u2013357"},{"key":"5324_CR20","doi-asserted-by":"publisher","first-page":"9947","DOI":"10.3390\/ijms25189947","volume":"25","author":"D Guo","year":"2024","unstructured":"Guo D, Liu Z, Zhou J et al (2024) Significance of programmed cell death pathways in neurodegenerative diseases. Int J Mol Sci 25:9947. https:\/\/doi.org\/10.3390\/ijms25189947","journal-title":"Int J Mol Sci"},{"key":"5324_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3389\/fnins.2020.00684","volume":"14","author":"R Ranganathan","year":"2020","unstructured":"Ranganathan R, Haque S, Coley K et al (2020) Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front Neurosci 14:684. https:\/\/doi.org\/10.3389\/fnins.2020.00684","journal-title":"Front Neurosci"},{"key":"5324_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41582-019-0161-9","volume":"15","author":"M Wajner","year":"2019","unstructured":"Wajner M (2019) Neurological manifestations of organic acidurias. Nat Rev Neurol 15:253\u2013271. https:\/\/doi.org\/10.1038\/s41582-019-0161-9","journal-title":"Nat Rev Neurol"},{"key":"5324_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.biopha.2018.12.101","volume":"111","author":"SH Tan","year":"2019","unstructured":"Tan SH, Karri V, Tay NWR et al (2019) Emerging pathways to neurodegeneration: dissecting the critical molecular mechanisms in alzheimer\u2019s disease, parkinson\u2019s disease. Biomed Pharmacother 111:765\u2013777. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.101","journal-title":"Biomed Pharmacother"},{"key":"5324_CR24","doi-asserted-by":"publisher","first-page":"240035","DOI":"10.1098\/rsob.240035","volume":"14","author":"M Gyimesi","year":"2024","unstructured":"Gyimesi M, Okolicsanyi RK, Haupt LM (2024) Beyond amyloid and tau: rethinking Alzheimer\u2019s disease through less explored avenues. Open Biol 14:240035. https:\/\/doi.org\/10.1098\/rsob.240035","journal-title":"Open Biol"},{"key":"5324_CR25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/ene.15211","volume":"29","author":"Z Hijazi","year":"2022","unstructured":"Hijazi Z, Yassi N, O\u2019Brien JT, Watson R (2022) The influence of cerebrovascular disease in dementia with lewy bodies and parkinson\u2019s disease dementia. Eur J Neurol 29:1254\u20131265. https:\/\/doi.org\/10.1111\/ene.15211","journal-title":"Eur J Neurol"},{"key":"5324_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma XR, Prudencio M, Koike Y et al (2022) TDP-43 represses cryptic exon inclusion in the FTD\u2013ALS gene UNC13A. Nature 603:124\u2013130. https:\/\/doi.org\/10.1038\/s41586-022-04424-7","journal-title":"Nature"},{"key":"5324_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5003902","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang J, Wang B, Zhou T (2022) The advance on frontotemporal dementia (FTD)\u2019s neuropathology and molecular genetics. Mediators Inflamm 2022:1\u20136. https:\/\/doi.org\/10.1155\/2022\/5003902","journal-title":"Mediators Inflamm"},{"key":"5324_CR28","doi-asserted-by":"publisher","first-page":"736978","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"E Srinivasan","year":"2021","unstructured":"Srinivasan E, Chandrasekhar G, Chandrasekar P et al (2021) Alpha-synuclein aggregation in parkinson\u2019s disease. Front Med 8:736978. https:\/\/doi.org\/10.3389\/fmed.2021.736978","journal-title":"Front Med"},{"key":"5324_CR29","doi-asserted-by":"publisher","first-page":"837579","DOI":"10.3389\/ftox.2022.837579","volume":"4","author":"M Nabi","year":"2022","unstructured":"Nabi M, Tabassum N (2022) Role of environmental toxicants on neurodegenerative disorders. Front Toxicol 4:837579. https:\/\/doi.org\/10.3389\/ftox.2022.837579","journal-title":"Front Toxicol"},{"key":"5324_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41398-022-02233-0","volume":"12","author":"H Xu","year":"2022","unstructured":"Xu H, Yang F (2022) The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia. Transl Psychiatry 12:464. https:\/\/doi.org\/10.1038\/s41398-022-02233-0","journal-title":"Transl Psychiatry"},{"key":"5324_CR31","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.arr.2024.102282","volume":"97","author":"N Siddiqui","year":"2024","unstructured":"Siddiqui N, Sharma A, Kesharwani A et al (2024) Exploring role of natural compounds in molecular alterations associated with brain ageing: a perspective towards nutrition for ageing brain. Ageing Res Rev 97:102282. https:\/\/doi.org\/10.1016\/j.arr.2024.102282","journal-title":"Ageing Res Rev"},{"key":"5324_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/ejn.16222","volume":"59","author":"A Cavallo","year":"2024","unstructured":"Cavallo A, Neumann W (2024) Dopaminergic reinforcement in the motor system: implications for parkinson\u2019s disease and deep brain stimulation. Eur J Neurosci 59:457\u2013472. https:\/\/doi.org\/10.1111\/ejn.16222","journal-title":"Eur J Neurosci"},{"key":"5324_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12035-016-0293-5","volume":"55","author":"S Singh","year":"2018","unstructured":"Singh S, Mishra A, Srivastava N et al (2018) Acetyl-l-Carnitine via upegulating dopamine D1 receptor and attenuating microglial activation prevents neuronal loss and improves memory functions in parkinsonian rats. Mol Neurobiol 55:583\u2013602. https:\/\/doi.org\/10.1007\/s12035-016-0293-5","journal-title":"Mol Neurobiol"},{"key":"5324_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Arachchige ASPM (2023) Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 10:200\u2013231. https:\/\/doi.org\/10.3934\/Neuroscience.2023017","journal-title":"AIMS Neurosci"},{"key":"5324_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnagi.2020.00004","volume":"12","author":"A Iarkov","year":"2020","unstructured":"Iarkov A, Barreto GE, Grizzell JA, Echeverria V (2020) Strategies for the treatment of parkinson\u2019s disease: beyond dopamine. Front Aging Neurosci 12:4. https:\/\/doi.org\/10.3389\/fnagi.2020.00004","journal-title":"Front Aging Neurosci"},{"key":"5324_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fnana.2020.00026","volume":"14","author":"A Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz A, Lopez-Lopez A, Labandeira CM, Labandeira-Garcia JL (2020) Interactions between the serotonergic and other neurotransmitter systems in the basal ganglia: role in parkinson\u2019s disease and adverse effects of L-DOPA. Front Neuroanat 14:26. https:\/\/doi.org\/10.3389\/fnana.2020.00026","journal-title":"Front Neuroanat"},{"key":"5324_CR37","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.3390\/ijms232113043","volume":"23","author":"LP Dolgacheva","year":"2022","unstructured":"Dolgacheva LP, Zinchenko VP, Goncharov NV (2022) Molecular and cellular interactions in pathogenesis of sporadic parkinson disease. Int J Mol Sci 23:13043. https:\/\/doi.org\/10.3390\/ijms232113043","journal-title":"Int J Mol Sci"},{"key":"5324_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuro.2021.07.006","volume":"86","author":"C Zheng","year":"2021","unstructured":"Zheng C, Zhang F (2021) New insights into pathogenesis of l-DOPA-induced dyskinesia. Neurotoxicology 86:104\u2013113. https:\/\/doi.org\/10.1016\/j.neuro.2021.07.006","journal-title":"Neurotoxicology"},{"key":"5324_CR39","doi-asserted-by":"publisher","DOI":"10.2174\/0118715273357909241126064951","author":"A Pannu","year":"2024","unstructured":"Pannu A, Goyal RK (2024) The potential role of dopamine pathways in the pathophysiology of depression: current advances and future aspects. CNS Neurol Disord - Drug Targets. https:\/\/doi.org\/10.2174\/0118715273357909241126064951","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"5324_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","volume":"12","author":"ZD Zhou","year":"2023","unstructured":"Zhou ZD, Yi LX, Wang DQ et al (2023) Role of dopamine in the pathophysiology of parkinson\u2019s disease. Transl Neurodegener 12:44. https:\/\/doi.org\/10.1186\/s40035-023-00378-6","journal-title":"Transl Neurodegener"},{"key":"5324_CR41","first-page":"235","volume-title":"Progress in Brain Research","author":"C Cepeda","year":"2014","unstructured":"Cepeda C, Murphy KPS, Parent M, Levine MS (2014) The role of dopamine in huntington\u2019s disease. Progress in Brain Research. Elsevier, Amsterdam, pp 235\u2013254"},{"key":"5324_CR42","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1177\/0963689717714105","volume":"26","author":"Y-H Chen","year":"2017","unstructured":"Chen Y-H, Huang EY-K, Kuo T-T et al (2017) Impact of traumatic brain injury on dopaminergic transmission. Cell Transplant 26:1156\u20131168. https:\/\/doi.org\/10.1177\/0963689717714105","journal-title":"Cell Transplant"},{"key":"5324_CR43","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.3390\/ijms22105313","volume":"22","author":"M Melnikov","year":"2021","unstructured":"Melnikov M, Pashenkov M, Boyko A (2021) Dopaminergic receptor targeting in multiple sclerosis: is there therapeutic potential? Int J Mol Sci 22:5313. https:\/\/doi.org\/10.3390\/ijms22105313","journal-title":"Int J Mol Sci"},{"key":"5324_CR44","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.4103\/NRR.NRR-D-24-00230","volume":"20","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liang Y, Gu Y (2025) The dopaminergic system and Alzheimer\u2019s disease. Neural Regen Res 20:2495\u20132512. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00230","journal-title":"Neural Regen Res"},{"key":"5324_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/archneur.1971.00490040046006","volume":"25","author":"JR Mendell","year":"1971","unstructured":"Mendell JR (1971) Amyotrophic lateral sclerosis: a study of central monoamine metabolism and therapeutic trial of levodopa. Arch Neurol 25:320. https:\/\/doi.org\/10.1001\/archneur.1971.00490040046006","journal-title":"Arch Neurol"},{"key":"5324_CR46","doi-asserted-by":"publisher","first-page":"118826","DOI":"10.1016\/j.lfs.2020.118826","volume":"265","author":"E Akyuz","year":"2021","unstructured":"Akyuz E, Polat AK, Eroglu E et al (2021) Revisiting the role of neurotransmitters in epilepsy: an updated review. Life Sci 265:118826. https:\/\/doi.org\/10.1016\/j.lfs.2020.118826","journal-title":"Life Sci"},{"key":"5324_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fnsyn.2018.00018","volume":"10","author":"A Gower","year":"2018","unstructured":"Gower A, Tiberi M (2018) The intersection of central dopamine system and stroke: potential avenues aiming at enhancement of motor recovery. Front Synaptic Neurosci 10:18. https:\/\/doi.org\/10.3389\/fnsyn.2018.00018","journal-title":"Front Synaptic Neurosci"},{"key":"5324_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA et al (2019) Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 6:96\u2013103. https:\/\/doi.org\/10.1002\/mdc3.12688","journal-title":"Mov Disord Clin Pract"},{"key":"5324_CR49","doi-asserted-by":"publisher","first-page":"122810","DOI":"10.1016\/j.saa.2023.122810","volume":"299","author":"ZV Reveguk","year":"2023","unstructured":"Reveguk ZV, Sych TS, Polyanichko AM et al (2023) Rapid and selective colorimetric determination of L-DOPA in human serum with silver nanoparticles. Spectrochim Acta A Mol Biomol Spectrosc 299:122810. https:\/\/doi.org\/10.1016\/j.saa.2023.122810","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"5324_CR50","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/brain\/awab123","volume":"144","author":"G Rossignoli","year":"2021","unstructured":"Rossignoli G, Kr\u00e4mer K, Lugar\u00e0 E et al (2021) Aromatic l -amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies. Brain 144:2443\u20132456. https:\/\/doi.org\/10.1093\/brain\/awab123","journal-title":"Brain"},{"key":"5324_CR51","doi-asserted-by":"publisher","first-page":"102798","DOI":"10.1016\/j.conb.2023.102798","volume":"83","author":"S Zhai","year":"2023","unstructured":"Zhai S, Cui Q, Simmons DV, Surmeier DJ (2023) Distributed dopaminergic signaling in the basal ganglia and its relationship to motor disability in parkinson\u2019s disease. Curr Opin Neurobiol 83:102798. https:\/\/doi.org\/10.1016\/j.conb.2023.102798","journal-title":"Curr Opin Neurobiol"},{"key":"5324_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cca.2021.08.009","volume":"522","author":"S Latif","year":"2021","unstructured":"Latif S, Jahangeer M, Maknoon Razia D et al (2021) Dopamine in parkinson\u2019s disease. Clin Chim Acta 522:114\u2013126. https:\/\/doi.org\/10.1016\/j.cca.2021.08.009","journal-title":"Clin Chim Acta"},{"key":"5324_CR53","volume-title":"Neuroscience","author":"D Purves","year":"2004","unstructured":"Purves D (2004) Neuroscience, 3rd edn. Sinauer Associates, , Sunderland, Mass","edition":"3"},{"key":"5324_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00397-2","author":"S Srivastav","year":"2023","unstructured":"Srivastav S, Cui X, Varela RB et al (2023) Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. Schizophrenia. https:\/\/doi.org\/10.1038\/s41537-023-00397-2","journal-title":"Schizophrenia"},{"key":"5324_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2022.1002960","author":"CR Gerfen","year":"2023","unstructured":"Gerfen CR (2023) Segregation of D1 and D2 dopamine receptors in the striatal direct and indirect pathways: an historical perspective. Front Synaptic Neurosci. https:\/\/doi.org\/10.3389\/fnsyn.2022.1002960","journal-title":"Front Synaptic Neurosci"},{"key":"5324_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.670346","author":"RM Ryan","year":"2021","unstructured":"Ryan RM, Ingram SL, Scimemi A (2021) Regulation of glutamate, GABA and dopamine transporter uptake, surface mobility and expression. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2021.670346","journal-title":"Front Cell Neurosci"},{"key":"5324_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508:1\u201312. https:\/\/doi.org\/10.1016\/j.abb.2010.12.017","journal-title":"Arch Biochem Biophys"},{"key":"5324_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"2023","unstructured":"Regensburger M, Ip CW, Kohl Z et al (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm 130:847\u2013861. https:\/\/doi.org\/10.1007\/s00702-023-02623-8","journal-title":"J Neural Transm"},{"key":"5324_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","volume":"282","author":"CP Ford","year":"2014","unstructured":"Ford CP (2014) The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 282:13\u201322. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.01.025","journal-title":"Neuroscience"},{"key":"5324_CR60","doi-asserted-by":"publisher","DOI":"10.4172\/2471-271X.1000120","author":"G Ayano","year":"2016","unstructured":"Ayano G (2016) Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures. J Ment Disord Treat. https:\/\/doi.org\/10.4172\/2471-271X.1000120","journal-title":"J Ment Disord Treat"},{"key":"5324_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00242","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2014.00242","journal-title":"Front Neurol"},{"key":"5324_CR62","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41531-023-00541-w","volume":"9","author":"C Rusch","year":"2023","unstructured":"Rusch C, Flanagan R, Suh H, Subramanian I (2023) To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson\u2019s disease. Npj Park Dis 9:98. https:\/\/doi.org\/10.1038\/s41531-023-00541-w","journal-title":"Npj Park Dis"},{"key":"5324_CR63","doi-asserted-by":"publisher","first-page":"1046910","DOI":"10.3389\/fneur.2023.1046910","volume":"14","author":"Z Zhong","year":"2023","unstructured":"Zhong Z, Ye M, Yan F (2023) A review of studies on gut microbiota and levodopa metabolism. Front Neurol 14:1046910. https:\/\/doi.org\/10.3389\/fneur.2023.1046910","journal-title":"Front Neurol"},{"key":"5324_CR64","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/9781119660699.ch19","volume-title":"Oral bioavailability and drug delivery","author":"L Wang","year":"2023","unstructured":"Wang L, Li X, Ying M et al (2023) Amino acid transporters. In: Hu M, Li X (eds) Oral bioavailability and drug delivery, 1st edn. Wiley, New Delhi, pp 361\u2013392","edition":"1"},{"key":"5324_CR65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/jpet.114.216317","volume":"351","author":"SMR Camargo","year":"2014","unstructured":"Camargo SMR, Vuille-dit-Bille RN, Mariotta L et al (2014) The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of parkinson\u2019s disease. J Pharmacol Exp Ther 351:114\u2013123. https:\/\/doi.org\/10.1124\/jpet.114.216317","journal-title":"J Pharmacol Exp Ther"},{"key":"5324_CR66","unstructured":"Mariotta L (2012) Amino acids: basolateral efflux and extracellular homeostasis control in vivo. University of Zurich"},{"key":"5324_CR67","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cphy.c130028","volume-title":"Comprehensive physiology","author":"V Makrides","year":"2014","unstructured":"Makrides V, Camargo SMR, Verrey F (2014) Transport of amino acids in the kidney. In: Terjung R (ed) Comprehensive physiology, 1st edn. Wiley, New Delhi, pp 367\u2013403","edition":"1"},{"key":"5324_CR68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/187152712800672436","volume":"11","author":"S Espinoza","year":"2012","unstructured":"Espinoza S, Manago F, Leo D et al (2012) Role of catechol-O-Methyltransferase (COMT)-dependent processes in parkinson\u2019s disease and L-DOPA treatment. CNS Neurol Disord - Drug Targets 11:251\u2013263. https:\/\/doi.org\/10.2174\/187152712800672436","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"5324_CR69","doi-asserted-by":"publisher","first-page":"119704","DOI":"10.1016\/j.biomaterials.2019.119704","volume":"232","author":"G Karthivashan","year":"2020","unstructured":"Karthivashan G, Ganesan P, Park S-Y et al (2020) Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson\u2019s disease: from preclinical to translational studies. Biomaterials 232:119704. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119704","journal-title":"Biomaterials"},{"key":"5324_CR70","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2020.1010015","author":"E-S Abdel-Nasser","year":"2020","unstructured":"Abdel-Nasser E-S, Sachin C, Khadeja AA et al (2020) A comprehensive review on management of Parkinson\u2019s disease, inclusive of drug discovery and pharmacological approaches. J Appl Pharm Sci. https:\/\/doi.org\/10.7324\/JAPS.2020.1010015","journal-title":"J Appl Pharm Sci"},{"key":"5324_CR71","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/B978-0-323-93273-8.00025-0","volume-title":"Cottrell & Patel\u2019s neuroanesthesia","author":"A Du","year":"2025","unstructured":"Du A, Culley DJ, Crosby G (2025) Neurologic disease and anesthesia. Cottrell & Patel\u2019s neuroanesthesia. Elsevier, Amsterdam, pp 490\u2013502"},{"key":"5324_CR72","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/pharmaceutics15122666","volume":"15","author":"BS Sivamaruthi","year":"2023","unstructured":"Sivamaruthi BS, Kapoor DU, Kukkar RR et al (2023) Mesoporous silica nanoparticles: types, synthesis, role in the treatment of alzheimer\u2019s disease, and other applications. Pharmaceutics 15:2666. https:\/\/doi.org\/10.3390\/pharmaceutics15122666","journal-title":"Pharmaceutics"},{"key":"5324_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","volume":"23","author":"A Lees","year":"2023","unstructured":"Lees A, Tolosa E, Stocchi F et al (2023) Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother 23:15\u201324. https:\/\/doi.org\/10.1080\/14737175.2023.2176220","journal-title":"Expert Rev Neurother"},{"key":"5324_CR74","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1039\/D2NA00524G","volume":"4","author":"OAA Alabrahim","year":"2022","unstructured":"Alabrahim OAA, Azzazy HME-S (2022) Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson\u2019s disease. Nanoscale Adv 4:5233\u20135244. https:\/\/doi.org\/10.1039\/D2NA00524G","journal-title":"Nanoscale Adv"},{"key":"5324_CR75","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/pharmaceutics15051503","volume":"15","author":"DD Nakmode","year":"2023","unstructured":"Nakmode DD, Day CM, Song Y, Garg S (2023) The management of parkinson\u2019s disease: an overview of the current advancements in drug delivery systems. Pharmaceutics 15:1503. https:\/\/doi.org\/10.3390\/pharmaceutics15051503","journal-title":"Pharmaceutics"},{"key":"5324_CR76","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/14737175.2022.2091436","volume":"22","author":"A Lenka","year":"2022","unstructured":"Lenka A, Di Maria G, Lamotte G et al (2022) Practical pearls to improve the efficacy and tolerability of levodopa in parkinson\u2019s disease. Expert Rev Neurother 22:489\u2013498. https:\/\/doi.org\/10.1080\/14737175.2022.2091436","journal-title":"Expert Rev Neurother"},{"key":"5324_CR77","doi-asserted-by":"crossref","unstructured":"Teerapattarakan N (2018) Neuroprotective effects of the standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsons disease model. Doctor of philosophy, Chulalongkorn University","DOI":"10.1016\/j.phymed.2018.04.028"},{"key":"5324_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/antiox9070583","volume":"9","author":"TY Kim","year":"2020","unstructured":"Kim TY, Leem E, Lee JM, Kim SR (2020) Control of reactive oxygen species for the prevention of parkinson\u2019s disease: the possible application of flavonoids. Antioxidants 9:583. https:\/\/doi.org\/10.3390\/antiox9070583","journal-title":"Antioxidants"},{"key":"5324_CR79","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/ijms23084148","volume":"23","author":"T-W Liu","year":"2022","unstructured":"Liu T-W, Chen C-M, Chang K-H (2022) Biomarker of neuroinflammation in parkinson\u2019s disease. Int J Mol Sci 23:4148. https:\/\/doi.org\/10.3390\/ijms23084148","journal-title":"Int J Mol Sci"},{"key":"5324_CR80","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/antiox11010170","volume":"11","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Mashima K (2022) Neuroprotection and disease modification by astrocytes and microglia in parkinson disease. Antioxidants 11:170. https:\/\/doi.org\/10.3390\/antiox11010170","journal-title":"Antioxidants"},{"key":"5324_CR81","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/metabo10110450","volume":"10","author":"JW B\u0142aszczyk","year":"2020","unstructured":"B\u0142aszczyk JW (2020) Energy metabolism decline in the aging brain\u2014Pathogenesis of neurodegenerative disorders. Metabolites 10:450. https:\/\/doi.org\/10.3390\/metabo10110450","journal-title":"Metabolites"},{"key":"5324_CR82","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/ijms222413384","volume":"22","author":"P Kowalczyk","year":"2021","unstructured":"Kowalczyk P, Sulejczak D, Kleczkowska P et al (2021) Mitochondrial oxidative stress\u2014A causative factor and therapeutic target in many diseases. Int J Mol Sci 22:13384. https:\/\/doi.org\/10.3390\/ijms222413384","journal-title":"Int J Mol Sci"},{"key":"5324_CR83","doi-asserted-by":"publisher","first-page":"12862","DOI":"10.3390\/ijms222312862","volume":"22","author":"R Kleppe","year":"2021","unstructured":"Kleppe R, Waheed Q, Ruoff P (2021) DOPA Homeostasis by dopamine: a control-theoretic view. Int J Mol Sci 22:12862. https:\/\/doi.org\/10.3390\/ijms222312862","journal-title":"Int J Mol Sci"},{"key":"5324_CR84","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.4103\/1673-5374.360289","volume":"18","author":"A Jurcau","year":"2023","unstructured":"Jurcau A, Jurcau C (2023) Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies. Neural Regen Res 18:1472. https:\/\/doi.org\/10.4103\/1673-5374.360289","journal-title":"Neural Regen Res"},{"key":"5324_CR85","doi-asserted-by":"publisher","first-page":"121814","DOI":"10.1016\/j.lfs.2023.121814","volume":"328","author":"D Neves","year":"2023","unstructured":"Neves D, Salazar IL, Almeida RD, Silva RM (2023) Molecular mechanisms of ischemia and glutamate excitotoxicity. Life Sci 328:121814. https:\/\/doi.org\/10.1016\/j.lfs.2023.121814","journal-title":"Life Sci"},{"key":"5324_CR86","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.3390\/ijms23169381","volume":"23","author":"F Wang","year":"2022","unstructured":"Wang F, Xie X, Xing X, Sun X (2022) Excitatory synaptic transmission in ischemic stroke: a new outlet for classical neuroprotective strategies. Int J Mol Sci 23:9381. https:\/\/doi.org\/10.3390\/ijms23169381","journal-title":"Int J Mol Sci"},{"key":"5324_CR87","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/cells12192336","volume":"12","author":"T Wang","year":"2023","unstructured":"Wang T, Sun Y, Dettmer U (2023) Astrocytes in parkinson\u2019s disease: from role to possible intervention. Cells 12:2336. https:\/\/doi.org\/10.3390\/cells12192336","journal-title":"Cells"},{"key":"5324_CR88","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.3390\/ijms252212448","volume":"25","author":"M Sidoryk-W\u0119grzynowicz","year":"2024","unstructured":"Sidoryk-W\u0119grzynowicz M, Adamiak K, Stru\u017cy\u0144ska L (2024) Targeting protein misfolding and aggregation as a therapeutic perspective in neurodegenerative disorders. Int J Mol Sci 25:12448. https:\/\/doi.org\/10.3390\/ijms252212448","journal-title":"Int J Mol Sci"},{"key":"5324_CR89","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/cells11050851","volume":"11","author":"Y Li","year":"2022","unstructured":"Li Y, Li S, Wu H (2022) Ubiquitination-Proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress. Cells 11:851. https:\/\/doi.org\/10.3390\/cells11050851","journal-title":"Cells"},{"key":"5324_CR90","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.arr.2023.101907","volume":"87","author":"E Possemato","year":"2023","unstructured":"Possemato E, La Barbera L, Nobili A et al (2023) The role of dopamine in NLRP3 inflammasome inhibition: implications for neurodegenerative diseases. Ageing Res Rev 87:101907. https:\/\/doi.org\/10.1016\/j.arr.2023.101907","journal-title":"Ageing Res Rev"},{"key":"5324_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smrv.2017.05.002","volume":"39","author":"F Raven","year":"2018","unstructured":"Raven F, Van Der Zee EA, Meerlo P, Havekes R (2018) The role of sleep in regulating structural plasticity and synaptic strength: implications for memory and cognitive function. Sleep Med Rev 39:3\u201311. https:\/\/doi.org\/10.1016\/j.smrv.2017.05.002","journal-title":"Sleep Med Rev"},{"key":"5324_CR92","doi-asserted-by":"publisher","first-page":"349","DOI":"10.14336\/AD.2015.0330","volume":"6","author":"R Claudia","year":"2015","unstructured":"Claudia R, Israel C, Benjam\u00edn F (2015) Dopamine receptors and neurodegeneration. Aging Dis 6:349. https:\/\/doi.org\/10.14336\/AD.2015.0330","journal-title":"Aging Dis"},{"key":"5324_CR93","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/00207454.2018.1545771","volume":"129","author":"J Fares","year":"2019","unstructured":"Fares J, Bou Diab Z, Nabha S, Fares Y (2019) Neurogenesis in the adult hippocampus: history, regulation, and prospective roles. Int J Neurosci 129:598\u2013611. https:\/\/doi.org\/10.1080\/00207454.2018.1545771","journal-title":"Int J Neurosci"},{"key":"5324_CR94","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/brainsci8090177","volume":"8","author":"R Hussain","year":"2018","unstructured":"Hussain R, Zubair H, Pursell S, Shahab M (2018) Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches. Brain Sci 8:177. https:\/\/doi.org\/10.3390\/brainsci8090177","journal-title":"Brain Sci"},{"key":"5324_CR95","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.15561","volume":"164","author":"N Nicastro","year":"2023","unstructured":"Nicastro N, Nencha U, Burkhard PR, Garibotto V (2023) Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. J Neurochem 164:346\u2013363. https:\/\/doi.org\/10.1111\/jnc.15561","journal-title":"J Neurochem"},{"key":"5324_CR96","doi-asserted-by":"publisher","first-page":"998932","DOI":"10.3389\/fnins.2022.998932","volume":"16","author":"F Alosaimi","year":"2022","unstructured":"Alosaimi F, Boonstra JT, Tan S et al (2022) The role of neurotransmitter systems in mediating deep brain stimulation effects in parkinson\u2019s disease. Front Neurosci 16:998932. https:\/\/doi.org\/10.3389\/fnins.2022.998932","journal-title":"Front Neurosci"},{"key":"5324_CR97","doi-asserted-by":"publisher","first-page":"108085","DOI":"10.1016\/j.neuropharm.2020.108085","volume":"171","author":"W Poewe","year":"2020","unstructured":"Poewe W, Seppi K, Marini K, Mahlknecht P (2020) New hopes for disease modification in parkinson\u2019s disease. Neuropharmacology 171:108085. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108085","journal-title":"Neuropharmacology"},{"key":"5324_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/pharmrev.122.000618","volume":"75","author":"B Channer","year":"2023","unstructured":"Channer B, Matt SM, Nickoloff-Bybel EA et al (2023) Dopamine, immunity, and disease. Pharmacol Rev 75:62\u2013158. https:\/\/doi.org\/10.1124\/pharmrev.122.000618","journal-title":"Pharmacol Rev"},{"key":"5324_CR99","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41401-020-0365-y","volume":"41","author":"Q Mao","year":"2020","unstructured":"Mao Q, Qin W, Zhang A, Ye N (2020) Recent advances in dopaminergic strategies for the treatment of parkinson\u2019s disease. Acta Pharmacol Sin 41:471\u2013482. https:\/\/doi.org\/10.1038\/s41401-020-0365-y","journal-title":"Acta Pharmacol Sin"},{"key":"5324_CR100","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13311-022-01309-5","volume":"20","author":"K Skovg\u00e5rd","year":"2023","unstructured":"Skovg\u00e5rd K, Barrientos SA, Petersson P et al (2023) Distinctive effects of D1 and D2 receptor agonists on cortico-basal ganglia oscillations in a rodent model of L-DOPA-Induced dyskinesia. Neurotherapeutics 20:304\u2013324. https:\/\/doi.org\/10.1007\/s13311-022-01309-5","journal-title":"Neurotherapeutics"},{"key":"5324_CR101","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y et al (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41:19\u201375. https:\/\/doi.org\/10.1007\/s40264-017-0590-6","journal-title":"Drug Saf"},{"key":"5324_CR102","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","volume":"8","author":"M Beckers","year":"2022","unstructured":"Beckers M, Bloem BR, Verbeek MM (2022) Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease. Npj Park Dis 8:56. https:\/\/doi.org\/10.1038\/s41531-022-00321-y","journal-title":"Npj Park Dis"},{"key":"5324_CR103","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for parkinson\u2019s disease: MDS-PD clinical diagnostic criteria. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"5324_CR104","doi-asserted-by":"publisher","first-page":"117309","DOI":"10.1016\/j.jns.2021.117309","volume":"422","author":"Y Song","year":"2021","unstructured":"Song Y, Gong T, Xiang Y et al (2021) Single-dose L-dopa increases upper brainstem GABA in Parkinson\u2019s disease: a preliminary study. J Neurol Sci 422:117309. https:\/\/doi.org\/10.1016\/j.jns.2021.117309","journal-title":"J Neurol Sci"},{"issue":"2","key":"5324_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.22514\/SV142.102018.12","volume":"14","author":"SJ Yun","year":"2018","unstructured":"Yun SJ, Lee SH, Ryu S, Choi SW, Kim HJ, Kang TK, Oh SC, Cho SJ (2018) Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera. Signa Vitae 14(2):75\u201377","journal-title":"Signa Vitae"},{"key":"5324_CR106","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ejn.14119","volume":"49","author":"EL Lane","year":"2019","unstructured":"Lane EL (2019) L- DOPA for parkinson\u2019s disease\u2014a bittersweet pill. Eur J Neurosci 49:384\u2013398. https:\/\/doi.org\/10.1111\/ejn.14119","journal-title":"Eur J Neurosci"},{"key":"5324_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.09.024","volume":"45","author":"KA Schindlbeck","year":"2017","unstructured":"Schindlbeck KA, Sch\u00f6nfeld S, Naumann W et al (2017) Characterization of diplopia in non-demented patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 45:1\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.024","journal-title":"Parkinsonism Relat Disord"},{"key":"5324_CR108","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00415-018-8940-6","volume":"266","author":"S Podvin","year":"2019","unstructured":"Podvin S, Reardon HT, Yin K et al (2019) Multiple clinical features of Huntington\u2019s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration. J Neurol 266:551\u2013564. https:\/\/doi.org\/10.1007\/s00415-018-8940-6","journal-title":"J Neurol"},{"key":"5324_CR109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1073858420972662","volume":"28","author":"C Cepeda","year":"2022","unstructured":"Cepeda C, Levine MS (2022) Synaptic dysfunction in huntington\u2019s disease: lessons from genetic animal models. Neuroscientist 28:20\u201340. https:\/\/doi.org\/10.1177\/1073858420972662","journal-title":"Neuroscientist"},{"key":"5324_CR110","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16:529\u2013546. https:\/\/doi.org\/10.1038\/s41582-020-0389-4","journal-title":"Nat Rev Neurol"},{"key":"5324_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nbd.2015.09.008","volume":"90","author":"P Guedes-Dias","year":"2016","unstructured":"Guedes-Dias P, Pinho BR, Soares TR et al (2016) Mitochondrial dynamics and quality control in huntington\u2019s disease. Neurobiol Dis 90:51\u201357. https:\/\/doi.org\/10.1016\/j.nbd.2015.09.008","journal-title":"Neurobiol Dis"},{"key":"5324_CR112","doi-asserted-by":"publisher","first-page":"180165","DOI":"10.1098\/rsob.180165","volume":"8","author":"Y-T Hsu","year":"2018","unstructured":"Hsu Y-T, Chang Y-G, Chern Y (2018) Insights into GABAA ergic system alteration in huntington\u2019s disease. Open Biol 8:180165. https:\/\/doi.org\/10.1098\/rsob.180165","journal-title":"Open Biol"},{"key":"5324_CR113","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.prdoa.2023.100212","volume":"9","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Hauser RA, Pahwa R et al (2023) Dopamine agonists in parkinson\u2019s disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clin Park Relat Disord 9:100212. https:\/\/doi.org\/10.1016\/j.prdoa.2023.100212","journal-title":"Clin Park Relat Disord"},{"key":"5324_CR114","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/aian.AIAN_221_19","volume":"23","author":"M Farrenburg","year":"2020","unstructured":"Farrenburg M, Gupta H (2020) Levodopa-responsive chorea: a review. Ann Indian Acad Neurol 23:211. https:\/\/doi.org\/10.4103\/aian.AIAN_221_19","journal-title":"Ann Indian Acad Neurol"},{"key":"5324_CR115","doi-asserted-by":"publisher","first-page":"107742","DOI":"10.1016\/j.jbc.2024.107742","volume":"300","author":"A Bayati","year":"2024","unstructured":"Bayati A, McPherson PS (2024) Alpha-synuclein, autophagy-lysosomal pathway, and lewy bodies: mutations, propagation, aggregation, and the formation of inclusions. J Biol Chem 300:107742. https:\/\/doi.org\/10.1016\/j.jbc.2024.107742","journal-title":"J Biol Chem"},{"key":"5324_CR116","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1042\/BST20180025","volume":"46","author":"T Briston","year":"2018","unstructured":"Briston T, Hicks AR (2018) Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention. Biochem Soc Trans 46:829\u2013842. https:\/\/doi.org\/10.1042\/BST20180025","journal-title":"Biochem Soc Trans"},{"key":"5324_CR117","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1792-9","volume":"135","author":"NL Rey","year":"2018","unstructured":"Rey NL, George S, Steiner JA et al (2018) Spread of aggregates after olfactory bulb injection of \u03b1-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol (Berl) 135:65\u201383. https:\/\/doi.org\/10.1007\/s00401-017-1792-9","journal-title":"Acta Neuropathol (Berl)"},{"key":"5324_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bpa.12168","volume":"25","author":"K Seidel","year":"2015","unstructured":"Seidel K, Mahlke J, Siswanto S et al (2015) The brainstem pathologies of parkinson\u2019s disease and dementia with lewy bodies. Brain Pathol 25:121\u2013135. https:\/\/doi.org\/10.1111\/bpa.12168","journal-title":"Brain Pathol"},{"key":"5324_CR119","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cger.2018.06.007","volume":"34","author":"AM Sanford","year":"2018","unstructured":"Sanford AM (2018) Lewy body dementia. Clin Geriatr Med 34:603\u2013615. https:\/\/doi.org\/10.1016\/j.cger.2018.06.007","journal-title":"Clin Geriatr Med"},{"key":"5324_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.10.004","author":"UC Dash","year":"2024","unstructured":"Dash UC, Bhol NK, Swain SK et al (2024) Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications. Acta Pharm Sin B. https:\/\/doi.org\/10.1016\/j.apsb.2024.10.004","journal-title":"Acta Pharm Sin B"},{"key":"5324_CR121","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3233\/JPD-240002","volume":"14","author":"P Borghammer","year":"2024","unstructured":"Borghammer P, Okkels N, Weintraub D (2024) Parkinson\u2019s disease and dementia with lewy bodies: one and the same. J Park Dis 14:383\u2013397. https:\/\/doi.org\/10.3233\/JPD-240002","journal-title":"J Park Dis"},{"key":"5324_CR122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41531-022-00279-x","volume":"8","author":"E Matar","year":"2022","unstructured":"Matar E, Ehgoetz Martens KA, Phillips JR et al (2022) Dynamic network impairments underlie cognitive fluctuations in lewy body dementia. Npj Park Dis 8:16. https:\/\/doi.org\/10.1038\/s41531-022-00279-x","journal-title":"Npj Park Dis"},{"key":"5324_CR123","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. The Lancet 397:2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"The Lancet"},{"key":"5324_CR124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64152","author":"AJ Maristany","year":"2024","unstructured":"Maristany AJ, Sa BC, Murray C et al (2024) Psychiatric manifestations of neurological diseases: a narrative review. Cureus. https:\/\/doi.org\/10.7759\/cureus.64152","journal-title":"Cureus"},{"key":"5324_CR125","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3181\/0707-MR-193","volume":"233","author":"S Vale","year":"2008","unstructured":"Vale S (2008) Current management of the cognitive dysfunction in parkinson\u2019s disease: how far have we come? Exp Biol Med 233:941\u2013951. https:\/\/doi.org\/10.3181\/0707-MR-193","journal-title":"Exp Biol Med"},{"key":"5324_CR126","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.3390\/cells11233736","volume":"11","author":"DK Kwon","year":"2022","unstructured":"Kwon DK, Kwatra M, Wang J, Ko HS (2022) Levodopa-Induced dyskinesia in parkinson\u2019s disease: pathogenesis and emerging treatment strategies. Cells 11:3736. https:\/\/doi.org\/10.3390\/cells11233736","journal-title":"Cells"},{"key":"5324_CR127","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/MS9.0000000000001664","volume":"86","author":"SA Khan","year":"2024","unstructured":"Khan SA, Khan S, Kausar H et al (2024) Insights into the management of Lewy body dementia: a scoping review. Ann Med Surg 86:930\u2013942. https:\/\/doi.org\/10.1097\/MS9.0000000000001664","journal-title":"Ann Med Surg"},{"key":"5324_CR128","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3390\/jcm9082329","volume":"9","author":"A Peraza-Delgado","year":"2020","unstructured":"Peraza-Delgado A, S\u00e1nchez-G\u00f3mez MB, G\u00f3mez-Salgado J et al (2020) Non-Pharmacological interventions towards preventing the triad osteoporosis-falls risk-hip fracture, in population older than 65 scoping review. J Clin Med 9:2329. https:\/\/doi.org\/10.3390\/jcm9082329","journal-title":"J Clin Med"},{"key":"5324_CR129","doi-asserted-by":"publisher","first-page":"101753","DOI":"10.1016\/j.disamonth.2024.101753","volume":"70","author":"F DeRosier","year":"2024","unstructured":"DeRosier F, Hibbs C, Alessi K et al (2024) Progressive supranuclear palsy: neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies. Dis Mon 70:101753. https:\/\/doi.org\/10.1016\/j.disamonth.2024.101753","journal-title":"Dis Mon"},{"key":"5324_CR130","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s11940-013-0261-6","volume":"15","author":"BP Boot","year":"2013","unstructured":"Boot BP, McDade EM, McGinnis SM, Boeve BF (2013) Treatment of dementia with lewy bodies. Curr Treat Options Neurol 15:738\u2013764. https:\/\/doi.org\/10.1007\/s11940-013-0261-6","journal-title":"Curr Treat Options Neurol"},{"key":"5324_CR131","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuroscience.2024.04.004","volume":"548","author":"Z Khan","year":"2024","unstructured":"Khan Z, Mehan S, Gupta GD, Narula AS (2024) Immune system dysregulation in the progression of multiple sclerosis: molecular insights and therapeutic implications. Neuroscience 548:9\u201326. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.04.004","journal-title":"Neuroscience"},{"key":"5324_CR132","doi-asserted-by":"crossref","unstructured":"Wang Q, Huang T, Zheng Z, et al (2023) Oligodendroglial precursors orchestrate immune network instigating early demyelination in experimental autoimmune encephalomyelitis","DOI":"10.1101\/2023.10.10.561804"},{"key":"5324_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5793817","volume":"2020","author":"MJ Tavassolifar","year":"2020","unstructured":"Tavassolifar MJ, Vodjgani M, Salehi Z, Izad M (2020) The influence of reactive oxygen species in the immune system and pathogenesis of multiple sclerosis. Autoimmune Dis 2020:1\u201314. https:\/\/doi.org\/10.1155\/2020\/5793817","journal-title":"Autoimmune Dis"},{"key":"5324_CR134","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12272-020-01270-x","volume":"43","author":"H-G Bae","year":"2020","unstructured":"Bae H-G, Kim TK, Suk HY et al (2020) White matter and neurological disorders. Arch Pharm Res 43:920\u2013931. https:\/\/doi.org\/10.1007\/s12272-020-01270-x","journal-title":"Arch Pharm Res"},{"key":"5324_CR135","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","volume":"18","author":"I Galea","year":"2021","unstructured":"Galea I (2021) The blood\u2013brain barrier in systemic infection and inflammation. Cell Mol Immunol 18:2489\u20132501. https:\/\/doi.org\/10.1038\/s41423-021-00757-x","journal-title":"Cell Mol Immunol"},{"key":"5324_CR136","doi-asserted-by":"publisher","first-page":"663053","DOI":"10.3389\/fnins.2021.663053","volume":"15","author":"MK Sen","year":"2021","unstructured":"Sen MK, Hossain MJ (2021) Oligodendrocyte-specific mechanisms of myelin thinning: implications for neurodegenerative diseases. Front Neurosci 15:663053. https:\/\/doi.org\/10.3389\/fnins.2021.663053","journal-title":"Front Neurosci"},{"key":"5324_CR137","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells10071639","volume":"10","author":"IH Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez IH, Villa-Gonz\u00e1lez M, Mart\u00edn G et al (2021) Glial cells as therapeutic approaches in brain ischemia-reperfusion injury. Cells 10:1639. https:\/\/doi.org\/10.3390\/cells10071639","journal-title":"Cells"},{"key":"5324_CR138","first-page":"269","volume-title":"Handbook of clinical neurology","author":"JM Gelfand","year":"2014","unstructured":"Gelfand JM (2014) Multiple sclerosis. Handbook of clinical neurology. Elsevier, Amsterdam, pp 269\u2013290"},{"key":"5324_CR139","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/apha.12476","volume":"216","author":"M Levite","year":"2016","unstructured":"Levite M (2016) Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol 216:42\u201389. https:\/\/doi.org\/10.1111\/apha.12476","journal-title":"Acta Physiol"},{"issue":"12","key":"5324_CR140","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/syn.21941","volume":"70","author":"E Del-Bel","year":"2016","unstructured":"Del-Bel E, Bortolanza M, Dos-Santos-Pereira M, Bariotto K, Raisman-Vozari R (2016) l-DOPA-induced dyskinesia in Parkinson\u2019s disease: are neuroinflammation and astrocytes key elements? Synapse 70(12):479\u2013500. https:\/\/doi.org\/10.1002\/syn.21941","journal-title":"Synapse"},{"key":"5324_CR141","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3389\/fneur.2018.00711","volume":"9","author":"M Muthuraman","year":"2018","unstructured":"Muthuraman M, Koirala N, Ciolac D et al (2018) Deep brain stimulation and L-DOPA therapy: concepts of action and clinical applications in parkinson\u2019s disease. Front Neurol 9:711. https:\/\/doi.org\/10.3389\/fneur.2018.00711","journal-title":"Front Neurol"},{"key":"5324_CR142","first-page":"558","volume":"10","author":"M Alqwaifly","year":"2016","unstructured":"Alqwaifly M (2016) Treatment responsive Holmes tremor: case report and literature review. Int J Health Sci 10:558","journal-title":"Int J Health Sci"},{"key":"5324_CR143","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J et al (2022) Phosphorylated Tau in alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 23:12841. https:\/\/doi.org\/10.3390\/ijms232112841","journal-title":"Int J Mol Sci"},{"key":"5324_CR144","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K et al (2021) The amyloid-\u03b2 pathway in alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"key":"5324_CR145","doi-asserted-by":"publisher","unstructured":"Department of Pharmacology, College of Pharmacy, Shri Venkateshwara University affiliation, Gajraula, India, Sethi P, C RDarwin, et al (2024) Mechanistic insights into tau protein-mediated regulation of oxidative stress. Chin J Appl Physiol. https:\/\/doi.org\/10.62958\/j.cjap.2024.028","DOI":"10.62958\/j.cjap.2024.028"},{"key":"5324_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P et al (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46:1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1","journal-title":"Inflammation"},{"key":"5324_CR147","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"key":"5324_CR148","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-24-01019","author":"I Jahan","year":"2024","unstructured":"Jahan I, Harun-Ur-Rashid M, Islam MdA et al (2024) Neuronal plasticity and its role in Alzheimer\u2019s disease and Parkinson\u2019s disease. Neural Regen Res. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-01019","journal-title":"Neural Regen Res"},{"key":"5324_CR149","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-0039-1681041","volume":"39","author":"N Villain","year":"2019","unstructured":"Villain N, Dubois B (2019) Alzheimer\u2019s disease including focal presentations. Semin Neurol 39:213\u2013226. https:\/\/doi.org\/10.1055\/s-0039-1681041","journal-title":"Semin Neurol"},{"key":"5324_CR150","doi-asserted-by":"publisher","DOI":"10.2174\/0126660822329981241007105405","author":"S Sarkar","year":"2024","unstructured":"Sarkar S, Bhui U, Kumar B et al (2024) Correlation between cognitive impairment and peripheral biomarkers - Significance of phosphorylated Tau and amyloid-\u03b2 in alzheimer\u2019s disease: a new insight. Curr Psychiatry Res Rev. https:\/\/doi.org\/10.2174\/0126660822329981241007105405","journal-title":"Curr Psychiatry Res Rev"},{"key":"5324_CR151","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1038\/s41598-020-62172-y","volume":"10","author":"AV Lebedev","year":"2020","unstructured":"Lebedev AV, Nilsson J, Lindstr\u00f6m J et al (2020) Effects of daily L-dopa administration on learning and brain structure in older adults undergoing cognitive training: a randomised clinical trial. Sci Rep 10:5227. https:\/\/doi.org\/10.1038\/s41598-020-62172-y","journal-title":"Sci Rep"},{"key":"5324_CR152","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/brainsci11080958","volume":"11","author":"P Menon","year":"2021","unstructured":"Menon P, Vucic S (2021) The upper motor neuron\u2014Improved knowledge from ALS and related clinical disorders. Brain Sci 11:958. https:\/\/doi.org\/10.3390\/brainsci11080958","journal-title":"Brain Sci"},{"key":"5324_CR153","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/cells11132049","volume":"11","author":"J Zhao","year":"2022","unstructured":"Zhao J, Wang X, Huo Z et al (2022) The impact of mitochondrial dysfunction in amyotrophic lateral sclerosis. Cells 11:2049. https:\/\/doi.org\/10.3390\/cells11132049","journal-title":"Cells"},{"key":"5324_CR154","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/jpm11070671","volume":"11","author":"O Pikatza-Menoio","year":"2021","unstructured":"Pikatza-Menoio O, Elicegui A, Bengoetxea X et al (2021) The skeletal muscle emerges as a new disease target in amyotrophic lateral sclerosis. J Pers Med 11:671. https:\/\/doi.org\/10.3390\/jpm11070671","journal-title":"J Pers Med"},{"key":"5324_CR155","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/j.jpainsymman.2023.06.029","volume":"66","author":"S Mercadante","year":"2023","unstructured":"Mercadante S, Al-Husinat L (2023) Palliative care in amyotrophic lateral sclerosis. J Pain Sympt Manage 66:e485\u2013e499. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.06.029","journal-title":"J Pain Sympt Manage"},{"key":"5324_CR156","doi-asserted-by":"publisher","first-page":"101790","DOI":"10.1016\/j.arr.2022.101790","volume":"83","author":"P Soares","year":"2023","unstructured":"Soares P, Silva C, Chavarria D et al (2023) Drug discovery and amyotrophic lateral sclerosis: emerging challenges and therapeutic opportunities. Ageing Res Rev 83:101790. https:\/\/doi.org\/10.1016\/j.arr.2022.101790","journal-title":"Ageing Res Rev"},{"key":"5324_CR157","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","volume":"37","author":"DS Malar","year":"2023","unstructured":"Malar DS, Thitilertdecha P, Ruckvongacheep KS et al (2023) Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs 37:399\u2013440. https:\/\/doi.org\/10.1007\/s40263-023-01007-6","journal-title":"CNS Drugs"},{"key":"5324_CR158","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","volume":"29","author":"B Alharbi","year":"2024","unstructured":"Alharbi B, Al-kuraishy HM, Al-Gareeb AI et al (2024) Role of GABA pathway in motor and non-motor symptoms in Parkinson\u2019s disease: a bidirectional circuit. Eur J Med Res 29:205. https:\/\/doi.org\/10.1186\/s40001-024-01779-7","journal-title":"Eur J Med Res"},{"key":"5324_CR159","doi-asserted-by":"publisher","first-page":"104979","DOI":"10.1016\/j.nbd.2020.104979","volume":"143","author":"H Nishijima","year":"2020","unstructured":"Nishijima H, Mori F, Arai A et al (2020) GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming. Neurobiol Dis 143:104979. https:\/\/doi.org\/10.1016\/j.nbd.2020.104979","journal-title":"Neurobiol Dis"},{"key":"5324_CR160","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira JB, Kumar A, Hall S et al (2023) DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical lewy body disease. Nat Aging 3:1201\u20131209. https:\/\/doi.org\/10.1038\/s43587-023-00478-y","journal-title":"Nat Aging"},{"key":"5324_CR161","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/brain\/awz261","volume":"142","author":"MF Dirkx","year":"2019","unstructured":"Dirkx MF, Zach H, Van Nuland A et al (2019) Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson\u2019s tremor. Brain 142:3144\u20133157. https:\/\/doi.org\/10.1093\/brain\/awz261","journal-title":"Brain"},{"key":"5324_CR162","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13041-024-01092-8","volume":"17","author":"H Lee","year":"2024","unstructured":"Lee H, Nam J, Hwang J-W et al (2024) L-DOPA regulates neuroinflammation and A\u03b2 pathology through NEP and ADAM17 in a mouse model of AD. Mol Brain 17:21. https:\/\/doi.org\/10.1186\/s13041-024-01092-8","journal-title":"Mol Brain"},{"key":"5324_CR163","doi-asserted-by":"publisher","first-page":"fcab116","DOI":"10.1093\/braincomms\/fcab116","volume":"3","author":"DDL Scheffer","year":"2021","unstructured":"Scheffer DDL, Freitas FC, Aguiar AS Jr et al (2021) Impaired dopamine metabolism is linked to fatigability in mice and fatigue in Parkinson\u2019s disease patients. Brain Commun 3:fcab116. https:\/\/doi.org\/10.1093\/braincomms\/fcab116","journal-title":"Brain Commun"},{"key":"5324_CR164","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s42494-023-00137-0","volume":"5","author":"KT Sumadewi","year":"2023","unstructured":"Sumadewi KT, Harkitasari S, Tjandra DC (2023) Biomolecular mechanisms of epileptic seizures and epilepsy: a review. Acta Epileptol 5:28. https:\/\/doi.org\/10.1186\/s42494-023-00137-0","journal-title":"Acta Epileptol"},{"key":"5324_CR165","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biomedicines11030783","volume":"11","author":"T-S Chen","year":"2023","unstructured":"Chen T-S, Huang T-H, Lai M-C, Huang C-W (2023) The role of glutamate receptors in epilepsy. Biomedicines 11:783. https:\/\/doi.org\/10.3390\/biomedicines11030783","journal-title":"Biomedicines"},{"key":"5324_CR166","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4103\/NRR.NRR-D-23-01766","volume":"20","author":"Q Qiu","year":"2025","unstructured":"Qiu Q, Yang M, Gong D et al (2025) Potassium and calcium channels in different nerve cells act as therapeutic targets in neurological disorders. Neural Regen Res 20:1258\u20131276. https:\/\/doi.org\/10.4103\/NRR.NRR-D-23-01766","journal-title":"Neural Regen Res"},{"key":"5324_CR167","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2147\/NDT.S142032","volume":"13","author":"T Chen","year":"2017","unstructured":"Chen T, Giri M, Xia Z et al (2017) Genetic and epigenetic mechanisms of epilepsy: a review. Neuropsychiatr Dis Treat 13:1841\u20131859. https:\/\/doi.org\/10.2147\/NDT.S142032","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5324_CR168","doi-asserted-by":"publisher","first-page":"903115","DOI":"10.3389\/fnmol.2022.903115","volume":"15","author":"KE Hills","year":"2022","unstructured":"Hills KE, Kostarelos K, Wykes RC (2022) Converging mechanisms of epileptogenesis and their insight in glioblastoma. Front Mol Neurosci 15:903115. https:\/\/doi.org\/10.3389\/fnmol.2022.903115","journal-title":"Front Mol Neurosci"},{"key":"5324_CR169","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1134\/S002209302103008X","volume":"57","author":"AV Zaitsev","year":"2021","unstructured":"Zaitsev AV, Amakhin DV, Dyomina AV et al (2021) Synaptic dysfunction in epilepsy. J Evol Biochem Physiol 57:542\u2013563. https:\/\/doi.org\/10.1134\/S002209302103008X","journal-title":"J Evol Biochem Physiol"},{"key":"5324_CR170","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fnins.2019.00611","volume":"13","author":"S Evangelisti","year":"2019","unstructured":"Evangelisti S, Pittau F, Testa C et al (2019) L-Dopa modulation of brain connectivity in parkinson\u2019s disease patients: a pilot EEG-fMRI study. Front Neurosci 13:611. https:\/\/doi.org\/10.3389\/fnins.2019.00611","journal-title":"Front Neurosci"},{"key":"5324_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2010.00139","author":"KS Rommelfanger","year":"2010","unstructured":"Rommelfanger KS (2010) Extrastriatal dopaminergic circuits of the basal ganglia. Front Neuroanat. https:\/\/doi.org\/10.3389\/fnana.2010.00139","journal-title":"Front Neuroanat"},{"key":"5324_CR172","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cns.12634","volume":"23","author":"L Gao","year":"2017","unstructured":"Gao L, Zhang J, Chan P, Wu T (2017) Levodopa effect on basal ganglia motor circuit in parkinson\u2019s disease. CNS Neurosci Ther 23:76\u201386. https:\/\/doi.org\/10.1111\/cns.12634","journal-title":"CNS Neurosci Ther"},{"key":"5324_CR173","doi-asserted-by":"publisher","first-page":"1531288","DOI":"10.3389\/fphar.2024.1531288","volume":"15","author":"S Khatoon","year":"2025","unstructured":"Khatoon S, Kalam N (2025) Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy. Front Pharmacol 15:1531288. https:\/\/doi.org\/10.3389\/fphar.2024.1531288","journal-title":"Front Pharmacol"},{"key":"5324_CR174","doi-asserted-by":"publisher","first-page":"eadp6301","DOI":"10.1126\/sciadv.adp6301","volume":"10","author":"BE Nielsen","year":"2024","unstructured":"Nielsen BE, Ford CP (2024) Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l -DOPA\u2013induced dyskinetic behaviors. Sci Adv 10:eadp6301. https:\/\/doi.org\/10.1126\/sciadv.adp6301","journal-title":"Sci Adv"},{"key":"5324_CR175","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mdc3.13992","volume":"11","author":"TG Guimar\u00e3es","year":"2024","unstructured":"Guimar\u00e3es TG, Parmera JB, Castro MAA et al (2024) X-Linked levodopa-responsive parkinsonism-epilepsy syndrome: a novel PGK1 mutation and literature review. Mov Disord Clin Pract 11:556\u2013566. https:\/\/doi.org\/10.1002\/mdc3.13992","journal-title":"Mov Disord Clin Pract"},{"key":"5324_CR176","doi-asserted-by":"publisher","first-page":"e034131","DOI":"10.1161\/JAHA.124.034131","volume":"13","author":"MH Rohner","year":"2024","unstructured":"Rohner MH, Gebhard C, Luft A et al (2024) Cardiac findings following cerebrovascular disease. J Am Heart Assoc 13:e034131. https:\/\/doi.org\/10.1161\/JAHA.124.034131","journal-title":"J Am Heart Assoc"},{"key":"5324_CR177","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s11064-022-03697-8","volume":"47","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Jia M, Wang Y et al (2022) Cell death mechanisms in cerebral ischemia-reperfusion injury. Neurochem Res 47:3525\u20133542. https:\/\/doi.org\/10.1007\/s11064-022-03697-8","journal-title":"Neurochem Res"},{"key":"5324_CR178","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4103\/1673-5374.293129","volume":"16","author":"H Mart\u00ednez-Coria","year":"2021","unstructured":"Mart\u00ednez-Coria H, Arrieta-Cruz I, Cruz M-E, L\u00f3pez-Vald\u00e9s H (2021) Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke. Neural Regen Res 16:433. https:\/\/doi.org\/10.4103\/1673-5374.293129","journal-title":"Neural Regen Res"},{"key":"5324_CR179","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fncel.2020.00051","volume":"14","author":"D Belov Kirdajova","year":"2020","unstructured":"Belov Kirdajova D, Kriska J, Tureckova J, Anderova M (2020) Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 14:51. https:\/\/doi.org\/10.3389\/fncel.2020.00051","journal-title":"Front Cell Neurosci"},{"key":"5324_CR180","doi-asserted-by":"publisher","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","volume":"316","author":"C Yang","year":"2019","unstructured":"Yang C, Hawkins KE, Dor\u00e9 S, Candelario-Jalil E (2019) Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol-Cell Physiol 316:C135\u2013C153. https:\/\/doi.org\/10.1152\/ajpcell.00136.2018","journal-title":"Am J Physiol-Cell Physiol"},{"key":"5324_CR181","doi-asserted-by":"publisher","first-page":"10226","DOI":"10.3390\/ijms221910226","volume":"22","author":"D Talhada","year":"2021","unstructured":"Talhada D, Marklund N, Wieloch T et al (2021) Plasticity-enhancing effects of levodopa treatment after stroke. Int J Mol Sci 22:10226. https:\/\/doi.org\/10.3390\/ijms221910226","journal-title":"Int J Mol Sci"},{"key":"5324_CR182","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.neuron.2020.01.039","volume":"105","author":"S Micera","year":"2020","unstructured":"Micera S, Caleo M, Chisari C et al (2020) Advanced neurotechnologies for the restoration of motor function. Neuron 105:604\u2013620. https:\/\/doi.org\/10.1016\/j.neuron.2020.01.039","journal-title":"Neuron"},{"key":"5324_CR183","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.addr.2018.12.012","volume":"148","author":"JM Obermeyer","year":"2019","unstructured":"Obermeyer JM, Ho E, Gracias A, Shoichet MS (2019) Influencing neuroplasticity in stroke treatment with advanced biomaterials-based approaches. Adv Drug Deliv Rev 148:204\u2013218. https:\/\/doi.org\/10.1016\/j.addr.2018.12.012","journal-title":"Adv Drug Deliv Rev"},{"key":"5324_CR184","doi-asserted-by":"publisher","first-page":"1330098","DOI":"10.3389\/fphar.2023.1330098","volume":"14","author":"GM Hasan","year":"2024","unstructured":"Hasan GM, Anwar S, Shamsi A et al (2024) The neuroprotective potential of phytochemicals in traumatic brain injury: mechanistic insights and pharmacological implications. Front Pharmacol 14:1330098. https:\/\/doi.org\/10.3389\/fphar.2023.1330098","journal-title":"Front Pharmacol"},{"key":"5324_CR185","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/pharmaceutics14010152","volume":"14","author":"D Baracaldo-Santamar\u00eda","year":"2022","unstructured":"Baracaldo-Santamar\u00eda D, Ariza-Salamanca DF, Corrales-Hern\u00e1ndez MG et al (2022) Revisiting excitotoxicity in traumatic brain injury: from bench to bedside. Pharmaceutics 14:152. https:\/\/doi.org\/10.3390\/pharmaceutics14010152","journal-title":"Pharmaceutics"},{"key":"5324_CR186","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/biology12081139","volume":"12","author":"MAM Freire","year":"2023","unstructured":"Freire MAM, Rocha GS, Bittencourt LO et al (2023) Cellular and molecular pathophysiology of traumatic brain injury: what have we learned so far? Biology 12:1139. https:\/\/doi.org\/10.3390\/biology12081139","journal-title":"Biology"},{"key":"5324_CR187","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.3390\/ijms25147741","volume":"25","author":"K Sadowski","year":"2024","unstructured":"Sadowski K, Zaj\u0105c W, Milanowski \u0141 et al (2024) Exploring fecal microbiota transplantation for modulating inflammation in parkinson\u2019s disease: a review of inflammatory markers and potential effects. Int J Mol Sci 25:7741. https:\/\/doi.org\/10.3390\/ijms25147741","journal-title":"Int J Mol Sci"},{"key":"5324_CR188","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41380-024-02443-6","volume":"29","author":"H Li","year":"2024","unstructured":"Li H, Watkins LR, Wang X (2024) Microglia in neuroimmunopharmacology and drug addiction. Mol Psychiatry 29:1912\u20131924. https:\/\/doi.org\/10.1038\/s41380-024-02443-6","journal-title":"Mol Psychiatry"},{"key":"5324_CR189","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.2147\/JIR.S511378","volume":"18","author":"Z-Q Hu","year":"2025","unstructured":"Hu Z-Q, Ma R, Sun J-Q et al (2025) Tenascin-C facilitates microglial polarization via TLR4\/MyD88\/NF-\u03baB pathway following subarachnoid hemorrhage. J Inflamm Res 18:3555\u20133570. https:\/\/doi.org\/10.2147\/JIR.S511378","journal-title":"J Inflamm Res"},{"key":"5324_CR190","doi-asserted-by":"publisher","first-page":"1103416","DOI":"10.3389\/fneur.2023.1103416","volume":"14","author":"J Qin","year":"2023","unstructured":"Qin J, Ma Z, Chen X, Shu S (2023) Microglia activation in central nervous system disorders: a review of recent mechanistic investigations and development efforts. Front Neurol 14:1103416. https:\/\/doi.org\/10.3389\/fneur.2023.1103416","journal-title":"Front Neurol"},{"key":"5324_CR191","doi-asserted-by":"publisher","first-page":"120448","DOI":"10.1016\/j.biomaterials.2020.120448","volume":"265","author":"J He","year":"2021","unstructured":"He J, Zhang N, Zhu Y et al (2021) MSC spheroids-loaded collagen hydrogels simultaneously promote neuronal differentiation and suppress inflammatory reaction through PI3K-Akt signaling pathway. Biomaterials 265:120448. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120448","journal-title":"Biomaterials"},{"key":"5324_CR192","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11064-023-04044-1","volume":"49","author":"R Liu","year":"2024","unstructured":"Liu R, Sun L, Shi X et al (2024) Increased expression of KNa1.2 channel by MAPK pathway regulates neuronal activity following traumatic brain injury. Neurochem Res 49:427\u2013440. https:\/\/doi.org\/10.1007\/s11064-023-04044-1","journal-title":"Neurochem Res"},{"key":"5324_CR193","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5114\/fn.2022.118184","volume":"60","author":"Y Feng","year":"2022","unstructured":"Feng Y, Ju Y, Yan Z et al (2022) Resveratrol attenuates autophagy and inflammation after traumatic brain injury by activation of PI3K\/Akt\/mTOR pathway in rats. Folia Neuropathol 60:153\u2013164. https:\/\/doi.org\/10.5114\/fn.2022.118184","journal-title":"Folia Neuropathol"},{"key":"5324_CR194","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1089\/neu.2014.3352","volume":"32","author":"HM Bramlett","year":"2015","unstructured":"Bramlett HM, Dietrich WD (2015) Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma 32:1834\u20131848. https:\/\/doi.org\/10.1089\/neu.2014.3352","journal-title":"J Neurotrauma"},{"key":"5324_CR195","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/1028415X.2020.1840035","volume":"25","author":"B Chen","year":"2022","unstructured":"Chen B, Zhao J, Zhang R et al (2022) Neuroprotective effects of natural compounds on neurotoxin-induced oxidative stress and cell apoptosis. Nutr Neurosci 25:1078\u20131099. https:\/\/doi.org\/10.1080\/1028415X.2020.1840035","journal-title":"Nutr Neurosci"},{"key":"5324_CR196","doi-asserted-by":"publisher","first-page":"13000","DOI":"10.3390\/ijms232113000","volume":"23","author":"A Fesharaki-Zadeh","year":"2022","unstructured":"Fesharaki-Zadeh A (2022) Oxidative stress in traumatic brain injury. Int J Mol Sci 23:13000. https:\/\/doi.org\/10.3390\/ijms232113000","journal-title":"Int J Mol Sci"},{"key":"5324_CR197","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/antiox12030731","volume":"12","author":"H Cheng","year":"2023","unstructured":"Cheng H, Wang P, Wang N et al (2023) Neuroprotection of NRF2 against ferroptosis after traumatic brain injury in mice. Antioxidants 12:731. https:\/\/doi.org\/10.3390\/antiox12030731","journal-title":"Antioxidants"},{"key":"5324_CR198","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-3-030-11339-1_18","volume-title":"Pituitary disorders of childhood","author":"RA Lal","year":"2019","unstructured":"Lal RA, Hoffman AR (2019) Pituitary response to traumatic brain injury. In: Kohn B (ed) Pituitary disorders of childhood. Springer International Publishing, Cham, pp 343\u2013352"},{"key":"5324_CR199","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","volume":"17","author":"G Sloan","year":"2021","unstructured":"Sloan G, Selvarajah D, Tesfaye S (2021) Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol 17:400\u2013420. https:\/\/doi.org\/10.1038\/s41574-021-00496-z","journal-title":"Nat Rev Endocrinol"},{"key":"5324_CR200","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3390\/ijms22041980","volume":"22","author":"M Laforgia","year":"2021","unstructured":"Laforgia M, Laface C, Calabr\u00f2 C et al (2021) Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. Int J Mol Sci 22:1980. https:\/\/doi.org\/10.3390\/ijms22041980","journal-title":"Int J Mol Sci"},{"key":"5324_CR201","doi-asserted-by":"publisher","first-page":"115734","DOI":"10.1016\/j.biopha.2023.115734","volume":"168","author":"SA Antar","year":"2023","unstructured":"Antar SA, Ashour NA, Sharaky M et al (2023) Diabetes mellitus: classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother 168:115734. https:\/\/doi.org\/10.1016\/j.biopha.2023.115734","journal-title":"Biomed Pharmacother"},{"key":"5324_CR202","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/00365521.2021.1942542","volume":"56","author":"B Roth","year":"2021","unstructured":"Roth B, Schiro DB, Ohlsson B (2021) Diseases which cause generalized peripheral neuropathy: a systematic review. Scand J Gastroenterol 56:1000\u20131010. https:\/\/doi.org\/10.1080\/00365521.2021.1942542","journal-title":"Scand J Gastroenterol"},{"key":"5324_CR203","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12974-022-02454-6","volume":"19","author":"Z Msheik","year":"2022","unstructured":"Msheik Z, El Massry M, Rovini A et al (2022) The macrophage: a key player in the pathophysiology of peripheral neuropathies. J Neuroinflammation 19:97. https:\/\/doi.org\/10.1186\/s12974-022-02454-6","journal-title":"J Neuroinflammation"},{"key":"5324_CR204","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1097\/j.pain.0000000000001528","volume":"160","author":"A DiAntonio","year":"2019","unstructured":"DiAntonio A (2019) Axon degeneration: mechanistic insights lead to therapeutic opportunities for the prevention and treatment of peripheral neuropathy. Pain 160:S17\u2013S22. https:\/\/doi.org\/10.1097\/j.pain.0000000000001528","journal-title":"Pain"},{"key":"5324_CR205","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.conb.2018.07.002","volume":"53","author":"E Asghari Adib","year":"2018","unstructured":"Asghari Adib E, Smithson LJ, Collins CA (2018) An axonal stress response pathway: degenerative and regenerative signaling by DLK. Curr Opin Neurobiol 53:110\u2013119. https:\/\/doi.org\/10.1016\/j.conb.2018.07.002","journal-title":"Curr Opin Neurobiol"},{"key":"5324_CR206","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuron.2015.12.023","volume":"89","author":"J Gerdts","year":"2016","unstructured":"Gerdts J, Summers DW, Milbrandt J, DiAntonio A (2016) Axon self-destruction: new links among SARM1, MAPKs, and NAD+ metabolism. Neuron 89:449\u2013460. https:\/\/doi.org\/10.1016\/j.neuron.2015.12.023","journal-title":"Neuron"},{"key":"5324_CR207","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/biomedicines9040399","volume":"9","author":"C Giorgio","year":"2021","unstructured":"Giorgio C, Zippoli M, Cocchiaro P et al (2021) Emerging role of C5 complement pathway in peripheral neuropathies: current treatments and future perspectives. Biomedicines 9:399. https:\/\/doi.org\/10.3390\/biomedicines9040399","journal-title":"Biomedicines"},{"key":"5324_CR208","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41582-019-0257-2","volume":"15","author":"JN Sleigh","year":"2019","unstructured":"Sleigh JN, Rossor AM, Fellows AD et al (2019) Axonal transport and neurological disease. Nat Rev Neurol 15:691\u2013703. https:\/\/doi.org\/10.1038\/s41582-019-0257-2","journal-title":"Nat Rev Neurol"},{"key":"5324_CR209","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1007\/s00415-020-10034-y","volume":"268","author":"J Berciano","year":"2021","unstructured":"Berciano J (2021) Axonal degeneration in Guillain-Barr\u00e9 syndrome: a reappraisal. J Neurol 268:3728\u20133743. https:\/\/doi.org\/10.1007\/s00415-020-10034-y","journal-title":"J Neurol"},{"key":"5324_CR210","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/978-3-031-69895-8_82","volume-title":"Autoimmune disease diagnosis","author":"N Gavrilova","year":"2024","unstructured":"Gavrilova N, Kamaeva E, Soprun L et al (2024) Guillain-Barre syndrome and other immune-mediated neuropathies. In: Shoenfeld Y, Cervera R, Espinosa G, Gershwin ME (eds) Autoimmune disease diagnosis. Springer Nature Switzerland, Cham, pp 577\u2013582"},{"key":"5324_CR211","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1007\/s12035-023-03342-7","volume":"60","author":"Q Lin","year":"2023","unstructured":"Lin Q, Li K, Chen Y et al (2023) Oxidative stress in diabetic peripheral neuropathy: pathway and mechanism-based treatment. Mol Neurobiol 60:4574\u20134594. https:\/\/doi.org\/10.1007\/s12035-023-03342-7","journal-title":"Mol Neurobiol"},{"key":"5324_CR212","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27086","volume":"63","author":"M Kazamel","year":"2021","unstructured":"Kazamel M, Stino AM, Smith AG (2021) Metabolic syndrome and peripheral neuropathy. Muscle Nerve 63:285\u2013293. https:\/\/doi.org\/10.1002\/mus.27086","journal-title":"Muscle Nerve"},{"key":"5324_CR213","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S2213-8587(19)30081-6","volume":"7","author":"D Selvarajah","year":"2019","unstructured":"Selvarajah D, Kar D, Khunti K et al (2019) Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 7:938\u2013948. https:\/\/doi.org\/10.1016\/S2213-8587(19)30081-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5324_CR214","doi-asserted-by":"publisher","first-page":"106292","DOI":"10.1016\/j.phrs.2022.106292","volume":"182","author":"I Sharma","year":"2022","unstructured":"Sharma I, Yadav KS, Mugale MN (2022) Redoxisome and diabetic retinopathy: pathophysiology and therapeutic interventions. Pharmacol Res 182:106292. https:\/\/doi.org\/10.1016\/j.phrs.2022.106292","journal-title":"Pharmacol Res"},{"key":"5324_CR215","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.3390\/ijms25158273","volume":"25","author":"DC Faro","year":"2024","unstructured":"Faro DC, Di Pino FL, Monte IP (2024) Inflammation, oxidative stress, and endothelial dysfunction in the pathogenesis of vascular damage: unraveling novel cardiovascular risk factors in fabry disease. Int J Mol Sci 25:8273. https:\/\/doi.org\/10.3390\/ijms25158273","journal-title":"Int J Mol Sci"},{"key":"5324_CR216","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1152\/physrev.00031.2008","volume":"89","author":"C Ruiz De Almodovar","year":"2009","unstructured":"Ruiz De Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89:607\u2013648. https:\/\/doi.org\/10.1152\/physrev.00031.2008","journal-title":"Physiol Rev"},{"key":"5324_CR217","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/ijms19010275","volume":"19","author":"J Shim","year":"2018","unstructured":"Shim J, Madsen J (2018) VEGF signaling in neurological disorders. Int J Mol Sci 19:275. https:\/\/doi.org\/10.3390\/ijms19010275","journal-title":"Int J Mol Sci"},{"key":"5324_CR218","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2020.08.020","volume":"91","author":"P Asthana","year":"2021","unstructured":"Asthana P, Zhang G, Sheikh KA, Him Eddie Ma C (2021) Heat shock protein is a key therapeutic target for nerve repair in autoimmune peripheral neuropathy and severe peripheral nerve injury. Brain Behav Immun 91:48\u201364. https:\/\/doi.org\/10.1016\/j.bbi.2020.08.020","journal-title":"Brain Behav Immun"},{"key":"5324_CR219","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/j.pain.0000000000001414","volume":"160","author":"S Liu","year":"2019","unstructured":"Liu S, Tang Y, Shu H et al (2019) Dopamine receptor D2, but not D1, mediates descending dopaminergic pathway\u2013produced analgesic effect in a trigeminal neuropathic pain mouse model. Pain 160:334\u2013344. https:\/\/doi.org\/10.1097\/j.pain.0000000000001414","journal-title":"Pain"},{"key":"5324_CR220","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s10072-020-04407-4","volume":"41","author":"DA Paul","year":"2020","unstructured":"Paul DA, Qureshi ARM, Rana AQ (2020) Peripheral neuropathy in parkinson\u2019s disease. Neurol Sci 41:2691\u20132701. https:\/\/doi.org\/10.1007\/s10072-020-04407-4","journal-title":"Neurol Sci"},{"key":"5324_CR221","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","volume":"19","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Laar TV, Cornblath DR et al (2013) Peripheral neuropathy in parkinson\u2019s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19:501\u2013507. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.006","journal-title":"Parkinsonism Relat Disord"},{"key":"5324_CR222","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12640-022-00619-y","volume":"41","author":"V Jain","year":"2023","unstructured":"Jain V, Behl T, Sehgal A et al (2023) Therapeutic molecular insights into the active engagement of cannabinoids in the therapy of parkinson\u2019s disease: a novel and futuristic approach. Neurotox Res 41:85\u2013102. https:\/\/doi.org\/10.1007\/s12640-022-00619-y","journal-title":"Neurotox Res"},{"key":"5324_CR223","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-030-82367-2_20","volume-title":"Hybrid PET\/MR neuroimaging","author":"L Giliberto","year":"2022","unstructured":"Giliberto L (2022) Neurology evaluation in dementia and neurodegenerative disease. In: Franceschi AM, Franceschi D (eds) Hybrid PET\/MR neuroimaging. Springer International Publishing, Cham, pp 227\u2013245"},{"key":"5324_CR224","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.npp.1300427","volume":"29","author":"N Ando","year":"2004","unstructured":"Ando N, Morimoto K, Watanabe T et al (2004) Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis. Neuropsychopharmacology 29:1251\u20131258. https:\/\/doi.org\/10.1038\/sj.npp.1300427","journal-title":"Neuropsychopharmacology"},{"key":"5324_CR225","doi-asserted-by":"publisher","first-page":"612073","DOI":"10.3389\/fnmol.2021.612073","volume":"14","author":"S Sharma","year":"2021","unstructured":"Sharma S, Tiarks G, Haight J, Bassuk AG (2021) Neuropathophysiological mechanisms and treatment strategies for post-traumatic epilepsy. Front Mol Neurosci 14:612073. https:\/\/doi.org\/10.3389\/fnmol.2021.612073","journal-title":"Front Mol Neurosci"},{"key":"5324_CR226","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1586\/14737175.8.5.781","volume":"8","author":"PB Wood","year":"2008","unstructured":"Wood PB (2008) Role of central dopamine in pain and analgesia. Expert Rev Neurother 8:781\u2013797. https:\/\/doi.org\/10.1586\/14737175.8.5.781","journal-title":"Expert Rev Neurother"},{"key":"5324_CR227","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00702-024-02812-z","volume":"131","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, V\u00e9csei L (2024) Revolutionizing our understanding of Parkinson\u2019s disease: Dr. Heinz Reichmann\u2019s pioneering research and future research direction. J Neural Transm 131:1367\u20131387. https:\/\/doi.org\/10.1007\/s00702-024-02812-z","journal-title":"J Neural Transm"},{"key":"5324_CR228","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood N, Jimenez-Shahed J (2023) Effective management of \u201cOFF\u201d episodes in parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr Dis Treat 19:247\u2013266. https:\/\/doi.org\/10.2147\/NDT.S273121","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5324_CR229","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40035-022-00317-x","volume":"11","author":"S Rota","year":"2022","unstructured":"Rota S, Urso D, Van Wamelen DJ et al (2022) Why do \u2018OFF\u2019 periods still occur during continuous drug delivery in Parkinson\u2019s disease? Transl Neurodegener 11:43. https:\/\/doi.org\/10.1186\/s40035-022-00317-x","journal-title":"Transl Neurodegener"},{"key":"5324_CR230","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","volume":"79","author":"V Cabreira","year":"2019","unstructured":"Cabreira V, Soares-da-Silva P, Massano J (2019) Contemporary options for the management of motor complications in parkinson\u2019s disease: updated clinical review. Drugs 79:593\u2013608. https:\/\/doi.org\/10.1007\/s40265-019-01098-w","journal-title":"Drugs"},{"key":"5324_CR231","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for parkinson\u2019s disease: current status and future opportunities. Mov Disord 35:1731\u20131744. https:\/\/doi.org\/10.1002\/mds.28215","journal-title":"Mov Disord"},{"key":"5324_CR232","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.29028","volume":"37","author":"K Kolman\u010di\u010d","year":"2022","unstructured":"Kolman\u010di\u010d K, Zupan\u010di\u010d NK, Tro\u0161t M et al (2022) Continuous dopaminergic stimulation improves cortical maladaptive changes in advanced parkinson\u2019s disease. Mov Disord 37:1465\u20131473. https:\/\/doi.org\/10.1002\/mds.29028","journal-title":"Mov Disord"},{"key":"5324_CR233","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/0113894501339455241101065040","volume":"26","author":"A Inamdar","year":"2025","unstructured":"Inamdar A, Gurupadayya B, Halagali P et al (2025) Unraveling neurological drug delivery: polymeric nanocarriers for enhanced blood-brain barrier penetration. Curr Drug Targets 26:243\u2013266. https:\/\/doi.org\/10.2174\/0113894501339455241101065040","journal-title":"Curr Drug Targets"},{"key":"5324_CR234","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s12010-023-04673-w","volume":"196","author":"S Chen","year":"2024","unstructured":"Chen S, Wang L, Hu Y et al (2024) High drug capacity of nano-levodopa-liposomes: preparation, in vitro release and brain-targeted research. Appl Biochem Biotechnol 196:3317\u20133330. https:\/\/doi.org\/10.1007\/s12010-023-04673-w","journal-title":"Appl Biochem Biotechnol"},{"key":"5324_CR235","unstructured":"(2023) Foslevodopa-Foscarbidopa (Vyalev): CADTH Reimbursement Recommendation: Indication: For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson\u2019s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-\/dyskinesia despite optimized treatment with available combinations of Parkinson\u2019s medicinal products. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)"},{"key":"5324_CR236","doi-asserted-by":"crossref","unstructured":"Debnath R, Ikbal AMA, Kargarzadeh H, et al (2024) Carbon nanodots-based polymer nanocomposite: a potential drug delivery armament of phytopharmaceuticals","DOI":"10.20944\/preprints202407.1934.v1"},{"key":"5324_CR237","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.31557\/APJCP.2024.25.10.3393","volume":"25","author":"S Paveethra","year":"2024","unstructured":"Paveethra S, Manisekaran H, Sasidharan S (2024) medicinal plants derived green carbon dots: synthesis, characterization and their potential applications in cancer therapy. Asian Pac J Cancer Prev 25:3393\u20133411. https:\/\/doi.org\/10.31557\/APJCP.2024.25.10.3393","journal-title":"Asian Pac J Cancer Prev"},{"key":"5324_CR238","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.nantod.2021.101328","volume":"41","author":"J Wu","year":"2021","unstructured":"Wu J, Cui X, Ke PC et al (2021) Nanomaterials as novel agents for amelioration of Parkinson\u2019s disease. Nano Today 41:101328. https:\/\/doi.org\/10.1016\/j.nantod.2021.101328","journal-title":"Nano Today"},{"key":"5324_CR239","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2174\/0113816128344571241018154506","volume":"31","author":"A Inamdar","year":"2025","unstructured":"Inamdar A, Gurupadayya B, Halagali P et al (2025) Cutting-edge strategies for overcoming therapeutic barriers in alzheimer\u2019s disease. Curr Pharm Des 31:598\u2013618. https:\/\/doi.org\/10.2174\/0113816128344571241018154506","journal-title":"Curr Pharm Des"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05324-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:47:50Z","timestamp":1760168870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05324-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":239,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05324-w","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}